Skip to main content
      Voclosporin and Steroids in Lupus Nephritis

      Dr. Jack Cush reports on abstract OP0059 presented at Eular 2024 in Vienna

      Dr. John Cush RheumNow

      4 weeks ago
      Voclosporin and Steroids in Lupus Nephritis Dr. Jack Cush reports on abstract OP0059 presented at Eular 2024 in Vienna, Austria. https://t.co/y9QPieV0py https://t.co/GzwntEJLve
      Mechanistic Promise in RA Doesn’t Always Mean Actual Gain

      Dr. David Liew reports on abstracts OP0007 and OP0069 at E

      Dr. John Cush RheumNow

      4 weeks ago
      Mechanistic Promise in RA Doesn’t Always Mean Actual Gain Dr. David Liew reports on abstracts OP0007 and OP0069 at Eular 2024 in Vienna, Austria. https://t.co/PcKtezJLCH https://t.co/N9tdgFN7Xq
      EULAR 2024: Monday’s Topic Panel (SLE) with RheumNow https://t.co/Ozl1DZKMuL

      Dr. John Cush RheumNow

      4 weeks ago
      EULAR 2024: Monday’s Topic Panel (SLE) with RheumNow https://t.co/Ozl1DZKMuL
      3 Big Lupus Themes from EULAR 2024

      Dr. Janet Pope discusses three hot topics in lupus at Eular 2024 in Vienna, Austria

      Dr. John Cush RheumNow

      4 weeks ago
      3 Big Lupus Themes from EULAR 2024 Dr. Janet Pope discusses three hot topics in lupus at Eular 2024 in Vienna, Austria, including abstracts POS0732 and OP0255. https://t.co/XD1EJW2nNE https://t.co/jALVfebb8t
      The final day of EULAR 2024 was rich in posters, Late-breaking oral presentations and EULAR updates and recommendations.  Below is a synopsis of the half-day's action.
      Dual seropositivity and shared epitopes in RA: friends or foes?

      Dual seropositivity, RF and/or anti-citrullinated prot

      Dr. John Cush RheumNow

      4 weeks ago
      Dual seropositivity and shared epitopes in RA: friends or foes? Dual seropositivity, RF and/or anti-citrullinated protein antibodies (ACPA) as well as shared epitope (SE) are known to be associated with poor prognosis and structural damage in RA. https://t.co/QcTHpgPV2Q https://t.co/TzueMr8M5T
      Belimumab’s Sustained Impact in Lupus

      SLE a chronic autoimmune multi-system inflammatory condition, can present with

      Dr. John Cush RheumNow

      4 weeks ago
      Belimumab’s Sustained Impact in Lupus SLE a chronic autoimmune multi-system inflammatory condition, can present with various, sometimes severe, clinical manifestations, leading to high levels of morbidity including impact on quality of life. https://t.co/4Gf5SJN5FG https://t.co/LxCjLQkaYQ
      Glucocorticoids (GC) have been the mainstay of treatment in SLE for nearly three quarters of a century. GC induce a range of anti-inflammatory effects, quickly relieve some symptoms and lower mortality in some life-threatening flares. However, they also have multiple side effects that limit the duration of treatment, as well as the dose used. Accordingly, the 2023 EULAR recommendations for SLE set a target dose of ≤5mg/day. Is low dose GC an
      A clinical trial in early axial spondyloarthritis (axSpA) demonstrated sustained inactive disease status in over 60% of patients. In axSpA patients with less than 1 year of disease symptoms, male sex, abstinence from smoking and lower BASDAI score at baseline were associated with higher chances of remission. Despite stable inactive disease state successfully induced by medication, drug-free remission in axSpA remains challenging.
      Can we prevent psoriatic arthritis?

      PsA affects up to 30% of PsO patients. Understanding factors that lead to PsA helps

      Dr. John Cush RheumNow

      4 weeks ago
      Can we prevent psoriatic arthritis? PsA affects up to 30% of PsO patients. Understanding factors that lead to PsA helps in early interventions. Most PsA patients have preceding PsO. https://t.co/03H4YrvxMe https://t.co/efUVaccSHn